Instead of targeting specific families of enzymes or other “druggable” proteins, there has always been the prospect of identifying cancer-specific genes that mimic the targets of the original cytotoxic chemotherapies, such as tubulins and other cytoskeletal proteins. The gene discussed is DNM2; the disease is cancer.